



Kaiser Foundation Health Plan of Washington Kaiser Foundation Health Plan of Washington Options, Inc. CONTRACT MANAGER NAME Provider Communications, RCR-A3W-04 PO Box 34262, Seattle WA 98124-1262

NOVEMBER 28, 2023

PASIREOTIDE (SIGNIFOR LAR) WILL REQUIRE PRIOR AUTHORIZATION APPROVAL

Dear Provider,

Effective March 1, 2024, pasireotide (Signifor LAR) will be added to the non-Medicare list of office administered drugs requiring prior authorization. This letter is a notification of the upcoming change in prior authorization criteria required before administering this medication under the medical benefit.

Kaiser Foundation Health Plan of Washington and Kaiser Foundation Health Plan of Washington, Options, Inc. (Kaiser Permanente) require prior authorization for a select group of injectable drugs that may be administered under the medical benefit in a physician's office or by home infusion. These reviews are intended to ensure consistent benefit adjudication as well as appropriate utilization in accordance with the Kaiser Permanente Pharmacy & Therapeutics Committee's evidence-based criteria for coverage.

Prior Authorization Criteria for Pasireotide (Signifor LAR):

DRUG NAME	COVERAGE CRITERIA
PASIREOTIDE	Initial Authorization For the treatment of Cushing's Disease in patients who: Have failure, contraindication, or intolerance to ketoconazole Initial Authorization: 90 days
	 Reauthorization Criteria: Patient has experienced a significant reduction in 24-hour urinary free cortisol (UFC) defined as ≥50% reduction in UFC from baseline.

Additional Information

A complete list of office-administered injectable drugs requiring prior authorization can be found on the Kaiser Permanente provider website at https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/officeinject.

To request prior authorization review, please use the Referral Request online form located on the Kaiser Permanente provider website at https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice. You can also fax your request to the Review Services department toll-free at 1-888-282-2685.

Thank you for the care you provide to our members, your patients. If you have any questions about this process, please call Review Services at 1-800-289-1363, Monday through Friday from 8 a.m. to 5 p.m.

Sincerely,

Gurpreet Rawat, MD, Chair

Pharmacy & Therapeutics Committee